Salix Pharmaceuticals Reports Q4 EPS of $0.40 vs. $0.49

by Benzinga Staff
February 28, 2011 4:20 PM | 9 seconds read |
Salix Pharmaceuticals, Ltd. SLXP today announced financial and operating results for the fourth quarter ended December 31, 2010. Net product revenues $118,498,000 EPS of $0.40
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: EarningsNewsHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!